- Home
- ULCC vs PVLA Comparison
ULCC vs PVLA Comparison
Compare ULCC & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ULCC | PVLA |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ULCC | PVLA |
|---|---|---|
| Price | $5.36 | $82.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 17 |
| Target Price | $5.67 | ★ $145.24 |
| AVG Volume (30 Days) | ★ 3.7M | 277.5K |
| Earning Date | 02-11-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,724,000,000.00 | N/A |
| Revenue This Year | $18.37 | N/A |
| Revenue Next Year | $12.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.89 | $16.65 |
| 52 Week High | $9.58 | $114.69 |
Technical Indicators
Market Signals| Indicator | ULCC | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 45.28 |
| Support Level | $4.93 | $76.50 |
| Resistance Level | $6.49 | $84.87 |
| Average True Range (ATR) | 0.50 | 6.34 |
| MACD | -0.01 | 0.26 |
| Stochastic Oscillator | 35.47 | 59.77 |
Price Performance
Historical ComparisonAbout ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.